Laboratory Safety Manual - Chapter 08: Reproductive Hazards

Title

Laboratory Safety Manual - Chapter 08: Reproductive Hazards

Purpose

This chapter supplements previous chapters by giving specific extra precautions, postings, training, and protective equipment necessary when working with reproductive hazards. These include chemical, biological, or radiological substances that can affect the developing fetus, or the reproductive health of the male or female parents. This chapter also outlines the UNC conceptus protection policy for laboratory workers who are pregnant or contemplating pregnancy. The appendix at the end of the chapter is a thorough (but not exhaustive) list of known reproductive toxins that might be present in your laboratory.

Table of Contents

  1. Introduction
  2. Laboratory Safety Plans
  3. Facility Requirements
  4. Protective Clothing
  5. Use of Primary Containment Equipment
  6. Use and Decontamination of Analytical Instrumentation
  7. Storage, Inventory, and Identification
  8. Working Quantities
  9. Laboratory Transport
  10. Protection of Vacuum Lines
  11. Packaging and Shipping
  12. Decontamination
  13. Disposal
  14. Animal Experimentation
  15. Reproductive Hazards and the Pregnant Employee
    1. Introduction
    2. Chemical and Radiological Reproductive Hazards
    3. Microbiological Reproductive Hazards
    4. Declared Pregnancy
    5. Conceptus Protection Program
    6. Action Levels
  16. Appendix 8-A: Reproductive Toxins List

I. Introduction

Work with reproductive hazards requires special containment practices in addition to those described in Chapter 6 for toxic chemicals and in the Biological Safety Manual. Reproductive hazards are defined by the OSHA Laboratory Standard as substances that cause chromosomal damage (mutagens) and substances with lethal or teratogenic (malformation) effects on fetuses. These can include chemicals, biological materials, and radioactive materials. The University policy for protecting pregnant employees is provided later in the section titled “Reproductive Hazards and the Pregnant Employee.” For a list of known reproductive toxins, refer to Appendix 8-A.

II. Laboratory Safety Plans

Laboratories working with reproductive hazards must include standard operating procedures in the Laboratory Safety Plan describing the hazards of the compounds or agents, safety precautions and emergency procedures in the event of a spill. Complete and submit a Laboratory Safety Plan online. In addition to the safety practices described for use of toxic materials, several other special safety precautions are necessary for reproductive toxins.

III. Facility Requirements

Establish a “designated area,” with access restricted to personnel who are aware of the hazards of the substances in use and the necessary precautions. A foot or elbow operated handwash facility and an eyewash facility must be available within the work area. A shower facility, other than emergency drench showers, must be located in the building.

Exhaust ventilation systems are designed to maintain an inflow of air from the corridor into the work area. The exhaust air from the work area must discharge directly to the outdoors, and clear of occupied buildings and air intakes. Exhaust air from the work area must not recirculate. The exhaust air from glove boxes must filter through high-efficiency particulate air (HEPA) and charcoal filters. EHS shall determine the need for and type of treatment for other primary containment equipment. Exhaust air treatment systems that remove toxic chemicals from the exhaust air by collection mechanisms such as filtration or absorption must operate in a manner that permits maintenance, in order to avoid direct contact with the collection medium. All exhaust air from primary containment equipment must discharge directly to the outdoors and disperse clear of occupied buildings and intakes. The EHS Director (or designee) must approve the purchase and installation of any non ducted hoods. Non-ducted hoods will not be approved for use with volatile chemicals. Approval will be granted only in exceptional cases, and only when particulate handling (e.g., weighing solids) is its sole use.

IV. Protective Clothing

Refer to Chapter 5: Protective Clothing and Equipment

Wear a full-fastened laboratory coat or a disposable jump suit in any area where known or suspected reproductive toxins are in use. Clean clothing must be provided weekly and cannot be worn outside of the work area. Following an obvious exposure, decontaminate or dispose immediately all contaminated clothing. Do not send contaminated clothing to the laundry until decontaminated. Wear appropriate gloves (Laboratory Safety Manual Appendix 5-B) when handling reproductive toxins. EHS recommends double gloving. Discard disposable gloves after each use and immediately after known contact with a reproductive toxin.

V. Use of Primary Containment Equipment

Procedures involving volatile chemicals, and those involving solid or liquid chemicals that may result in the generation of aerosols, must occur in a chemical fume hood, biological safety cabinet, glove box, or other suitable containment equipment. Examples of aerosol-producing procedures include: opening closed vessels; transfer operations; weighing; preparing feed mixtures; and the application, injection or intubation of a chemical into experimental animals. Class II, type B biological safety cabinets are suitable for the conduct of tissue culture and other biological procedures involving reproductive toxins. The Principal Investigator is to obtain guidance from EHS on the selection and use of Class II biological safety cabinets. For more information on biological safety cabinets, refer to Chapter 16: Biological Safety Cabinets. Primary containment equipment used for reproductive toxins must display a label bearing the legend: CAUTION – REPRODUCTIVE TOXIN, Authorized Personnel Only. The examples below in Figure 8.1, Figure 8.2, and Figure 8.3 are available on the EHS Safety Labels webpage for printing.

Figure 8.1














Figure 8.1 - Label for storage areas or primary containment equipment where reproductive toxins are present.

A clean bench (Chapter 16, Section III) is a laminar flow cabinet that provides a flow of filtered air over the work service and offers product protection, not personnel protection. Do not use reproductive toxins in them. Clean benches are posted by the lab or EHS with the following information (Figure 8.2):

Figure 8.2














Figure 8.2 - Example posting for clean benches.

VI. Use and Decontamination of Analytical Instrumentation

Analytical instruments used with reproductive toxins must be entirely within a laboratory hood. When this is impossible, capture the vapors or aerosols produced by these instruments through local exhaust ventilation at the site of their production. When you remove a sample from the analytical instrument, place it in a tightly stoppered sample tube, or otherwise safeguarded from contaminating the laboratory. Do not use contaminated analytical equipment until it has been completely decontaminated. The following are some decontamination guidelines. Contact EHS if you have additional questions about equipment decontamination.

Safely remove, drain, or discharge chemicals from the equipment, collecting the chemicals for re-use or hazardous waste disposal. If applicable, use an inert gas or liquid to purge the chemical residues. In some cases, the rinsate might require disposal as hazardous waste. For equipment with non-permeable surfaces, decontaminate by scrubbing with warm, soapy water. For equipment that also might contain biological contamination, follow the soapy water wash with a 1:10 bleach solution soak. Rinse the equipment after at least 10 minutes contact time with the bleach.

VII. Storage, Inventory and Identification

Store stock quantities of reproductive toxins in designated storage areas. Post these storage areas with signs bearing the legend: CAUTION – REPRODUCTIVE TOXIN, Authorized Personnel Only (Figure 8.1).

Label all storage vessels containing stock quantities with the following information: CAUTION – REPRODUCTIVE TOXIN (Figure 8.3 or similar). This smaller label, which does not include the “Authorized Personnel Only” statement necessary for containment equipment or storage areas, is available at EHS Safety Labels webpage.

Figure 8.3





Figure 8.3 - Label for storage vessels that contain reproductive toxins.

VIII. Working Quantities

Keep quantities of reproductive toxins in the work area to a minimum. Quantities should not normally exceed the amounts required for use in one week. Use the label depicted in Figure 8.3 (or similar) for storage vessels containing working quantities of reproductive toxins.

IX. Laboratory Transport

Place storage vessels containing reproductive toxins in an unbreakable outer container before transporting them from storage areas to laboratory work areas. Place contaminated materials to transfer from work areas to disposal areas in a closed plastic bag or other suitable impermeable and sealed primary container, and place the primary container in a durable outer container before transporting. Label the outer container with both the name of the substance and the hazard information from Figure 8.3.

X. Protection of Vacuum Lines

Each vacuum service, including water aspirators, must have protection via an absorbent or liquid trap and a HEPA filter to prevent entry of any reproductive toxin into the system. When using a volatile chemical, use a separate vacuum pump or other device placed in an appropriate laboratory hood.

XI. Packaging and Shipping

Package reproductive toxins to withstand shocks, pressure changes, or other conditions that could cause the leakage of contents incident to ordinary handling during transportation. Shipments must be in accordance with DOT and IATA regulations. These regulations state that you must receive specific training in order to ship a hazardous material. The EHS website has more information regarding training and guidance on shipping and labeling.

XII. Decontamination

If chemical, biological, or radioactive reproductive hazardous materials are spilled, this must be addressed immediately.  Depending on the material, they must be either: inactivated using a procedure that decomposes the hazardous material or they must be absorbed by appropriate means, collected, and disposed of through EHS.  After inactivating or absorbing the spilled material, spill areas must be thoroughly cleaned with soap and water, while collecting all cleaning materials for disposal through EHS.

XIII. Disposal

EHS must approve all plans for handling and ultimate disposal of contaminated wastes. Write these into the Laboratory Safety Plan, Schedule B, and fully describe the reproductive toxins in your waste stream when submitting an online hazardous materials pick up request through EHS. Refer to Chapter 12: Management of Laboratory Wastes for additional guidance.

XIV. Animal Experimentation

In all circumstances, research and animal care personnel must wear the appropriate protective apparel or equipment required for the location when entering Division of Comparative Medicine animal housing facilities or procedure rooms (refer to Chapter 14: Safe Handling of Laboratory Animals). As discussed in Chapter 5, comfort masks are not respirators. The comfort masks provided in several DCM facilities do not protect you from airborne exposures; instead, they protect the laboratory animals from your exhalations. Personnel with exposure to airborne particulates contaminated with reproductive toxins without the use of primary containment must wear an appropriate respirator of N95 or higher protection, rather than a comfort mask. Refer to the Respiratory Protection section of Chapter 5: Protective Clothing and Equipment, for a description of respirator types.

EHS must approve the selection and use of respirators, and wearers must participate in the UNC Respiratory Protection Program.

Do not wear the comfort mask or respirator outside of the animal room or procedure room. For tight-fitting cartridge respirators, dispose of used filters and decontaminate the respirator housing daily.

XV. Reproductive Hazards and the Pregnant Employee

A. Introduction

Reproductive toxins are defined by the OSHA Laboratory Standard as substances that cause chromosomal damage (mutagens) and/or substances with lethal or teratogenic (malformation) effects on fetuses. Teratogens may affect the conceptus at any stage of its development, from fertilization to birth, although damage is most likely during the first 8 to 10 weeks of pregnancy. Mutagens can also affect conceptus development, or prevent fertilization entirely by damaging the egg or sperm. In addition, there are microbiological agents that can cause maternal morbidity, miscarriage, fetal death or birth defects.

Teratogens are chemical and physical agents that interfere with normal embryonic development. Teratogens differ from mutagens in that there must be a developing fetus. Reproductive toxins may produce congenital malformations or death of the fetus without inducing damage to the pregnant woman. In general, you should consider carcinogenic, mutagenic and teratogenic chemicals hazards to reproductive health. Even though OSHA has established hazardous material exposure limits, a developing fetus can suffer adverse effects at lower doses than those considered safe for adults. Thus, you must keep exposures as low as reasonably achievable to minimize reproductive health hazards.

UNC is committed to providing additional protection for the conceptus, and establish specific procedures to protect pregnant employees. Control of employee exposures will occur without economic penalty or loss of job opportunity, including, if necessary, consideration for work assignment changes, consistent with University personnel policy. Assuring protection from exposures to radiation and/or chemicals for the conceptus requires full cooperation of the employee with the Department of Environment, Health and Safety (EHS). If you wish to take advantage of this policy, contact EHS as soon as possible after determining or contemplating pregnancy, to ensure implementation of these policies.

B. Chemical and Radiological Reproductive Hazards

A thorough list of known reproductive toxins is found in Appendix 8-A to this Chapter. This list includes agents that cause fetal developmental toxicity, damage the male/female reproductive cells, or other difficulty with conception. Examples of reproductive toxins commonly found in laboratories include:

  • 1,3-Butadiene
  • Ethylene thiourea
  • Arsenic
  • Fluorouracil
  • Benzene
  • Halothane
  • Cadmium
  • Ionizing radiation
  • Carbon disulfide
  • Lead
  • Dibromochloropropane
  • Mercury compounds
  • Ethylene dibromide
  • Polychlorinated biphenols (PCBs)
  • Ethylene glycol monomethyl (and ethyl) ethers
  • Toluene
  • Ethylene oxide
  • Urethane

Please refer to Appendix 8-A for a thorough listing.

C. Microbiological Reproductive Hazards

Certain microbiological agents can cause miscarriages, fetal death and birth defects. Employees can be exposed to these agents via splashes or contact with mucous membranes, needlesticks or ingestion. The following agents are known to be reproductive hazards:

  • Cytomegalovirus (CMV). CMV is a known teratogen and congenital infection can cause mental retardation, cerebral palsy, epilepsy, vision and hearing problems especially during the first 20 weeks of fetal development.
  • Hepatitis A, B, C. Prenatal infection can cause prematurity and psychomotor retardation.
  • Human Immunodeficiency Virus (HIV). HIV can affect fertility. HIV can also be transmitted to the fetus.
  • Human Parvovirus (Fifth Disease). Prenatal infection with human parvovirus can cause fetal edema and death. Intrauterine infection may cause fetal anaemia.
  • Listeria monocytogenes. This bacterium is found in a variety of animals including mammals and birds so is of special concern to employees handling animals. Perinatal infections occur transplacentally and can result in abortion, stillbirth, meningitis, endocarditis, or septicemia.
  • Rubella virus (German measles). Congenital rubella syndrome (CRS) may occur in infants born to women who had rubella during the first trimester. This can lead to fetal death, spontaneous abortions, congenital malformations of the eyes, ears and heart, mental retardation and/or poor childhood growth. The risk decreases with fetal development.
  • Toxoplasma gondii (toxoplasmosis). Congenital cases can result in abortion and stillbirth. Live births may result in central nervous system disorders, hydrocephaly, or mental retardation. Transplacental infection is least likely during the first trimester, but these cases are the most severe. Cats can carry this disease and employees conducting experiments with cats may need to take additional precautions.
  • Varicella virus (Chicken Pox). Congenital infection can cause limb atrophy, microcephaly, cortical atrophy, motor, sensory and eye problems. Infection during the first trimester can cause miscarriage, muscular atrophy, clubbed foot, CNS disease and cataracts in the fetus.

This list is not all-inclusive and EHS will evaluate work exposures to all infectious materials once an employee has declared her pregnancy.

D. Declared Pregnancy

If you wish the University to be involved in protecting your fetus, and exposures to the fetus kept below the 500 millirems limit if you are a radiation worker, you must declare your actual, suspected, or planned pregnancy to your supervisor and EHS in writing, or by e-mail. The University’s responsibility for conceptus protection begins only after receipt of this notice of pregnancy, or intended pregnancy, to your supervisor and EHS. The involvement of supervisors is an essential part of the University’s safety management. EHS urges every potentially pregnant employee to consider her supervisor’s safety responsibilities and freely involve the supervisor in all work-related situations.

E. Conceptus Protection Program

Following written or e-mail notice of pregnancy or intended pregnancy to the EHS Director, Biological Safety Officer, Chemical Hygiene Officer, or Radiation Safety Officer (RSO), EHS institutes a Conceptus Protection Program (CPP). The CPP consists of three elements.

1. Confidential Conferences

Conferences include the employee, her supervisor, and EHS specialists. The employee is provided a copy of this policy and other pertinent literature on protecting pregnant employees from chemical, biological and radiological exposures. Following the conference, EHS sends an assessment report to the employee and supervisor relating findings and recommendations of work involving hazardous materials. In some cases, adjustments should be made in work responsibilities, if practicable, to avoid higher risk operations.

An additional interview is available with an occupational health nurse or physician at the University Employee Occupational Health Clinic. This interview allows the employee to express concerns and to ask questions about reproductive and developmental health. A review of an occupational and reproductive health questionnaire facilitates collection of employee-specific information, assists the employee in formulating concerns about chemical and physical hazards, and provides structure and focus for the interview. A preconception planning stage is also available. Obstetric specialists are available for consultation or referral for any specific concerns.

EHS understands that employees may choose to maintain their pregnancy status as personally confidential for a time. Any employee may still receive safety information about pregnancy and chemical, biological, and radiological exposures at any time from EHS without declaring her pregnancy status.

2. EHS Review of Laboratory Safety

EHS will conduct a review of the laboratory or worksite safety plan to ensure that it provides appropriate guidance to protect workers and prevent occupational exposures. EHS inspects the work place to ensure that adequate engineering controls, such as laboratory hoods, are provided, and that safe handling procedures and the use of personal protective equipment are in place. Employees have the responsibility of adhering to University safety procedures described in the Laboratory (or worksite) Safety Plan, the Health and Safety Manual, Laboratory Safety Manual, Biological Safety Manual and the Radiation Safety Manual.

3. Radiation and Chemical Exposure Monitoring

EHS will monitor employee exposures levels for radiation and any chemicals of concern, especially those with evidence of reproductive toxicity. The employee and principal investigator, or supervisor, shall receive a copy of the monitoring report. The goal is to keep all exposures as low as reasonably achievable.

EHS performs the personnel radiation monitoring through the Radiation Safety section. EHS assigns the radiation employee a monthly radiation badge and/or places her on a monthly bioassay program.

F. Action Levels

1. Radiation Exposures

Current investigational radiation dose limits for declared pregnant or planned pregnancy employees will direct the RSO in evaluating reported doses. The North Carolina Regulations for Protection Against Radiation has established a radiation dose limit of 500 millirems for the conceptus during the entire gestation period.

Action Level I:

Employees with exposures greater than 30 millirems in a month. The RSO or designee shall send a written description of the dose report statistics, including the dose history for the previous two monitoring periods, to the person involved with a copy to the Authorized User. EHS asks the individual and their supervisor to review his or her radiation safety procedures and work habits in an effort to maintain all doses as low as reasonably achievable. Health physics reviews and consultation are available.

Action Level II:

Greater than 40 millirems in a month. The RSO shall conduct a direct investigation of the situation, including an interview with the person involved. The RSO prepares a written investigation report, including trends over the past one year (as available) for that person. The RSO provides a copy of the report to the employee for review and signature. Conclusions drawn from the investigation provide a basis for confirming or modifying the dose and for establishing corrective actions to undertake.

When the occupational radiation dose of a declared radiation employee exceeds 50 millirems in a month since declaration, the employee may request:

  • Maternity leave (for those employees actually pregnant)
  • Other paid leave
  • Leave without pay
  • Reassignment within their work unit
  • Transfer

The supervisor should respond to requests in accordance with Human Resources personnel policies.

EHS and the Radiation Protection Section of the NC Department of Environment and Natural Resources accept doses reported from personnel monitoring badges generally as an uncorrected guide to any conceptus dose. If personnel monitoring results indicate the possibility of a conceptus dose in excess of the 500-millirem limit, a special investigation will result. The investigation will take into full consideration the type and energy of radiation involved, protective shielding that might have mitigated conceptus dose, and shielding afforded by the mother’s body. The employee and EHS will discuss the investigation results, and a written report provided.

2. Chemical Exposures

As stated earlier, the goal is to keep all exposures to both radiation and chemicals as low as reasonably achievable. The actions taken in response to a measured chemical exposure depend on the specific circumstances and chemicals involved. However, as a general rule, if any exposure measurements exceed 10% of the threshold limit value (TLV) or permissible exposure limit (PEL) action will be taken to prevent further exposure by instituting engineering controls, improved work practices, personal protective equipment (PPE), or job reassignment.

3. Microbiological Exposures

There are no action levels for microbiological agents. Many of the agents listed above can be safely handled at Biosafety Level 2 practices and containment (culturing HIV requires Biosafety Level 3 practices). Biosafety Level 2 practices include wearing gloves, labcoats and eye protection, conducting any aerosol generating procedures inside of a biological safety cabinet, decontamination of surfaces, frequent handwashing, and no eating, drinking, smoking or handling contacts in areas where infectious materials are handled. Please refer to the UNC Biological Safety Manual for more detailed information. These practices are required to protect the employee; however, some procedures conducted in the laboratory may be higher risk for pregnant employees and should be evaluated by EHS. In addition, the risks to the fetus from exposure to these pathogens may warrant restriction from use during a pregnancy. EHS in consultation with the employee and their supervisor will determine when restriction or additional personal protective equipment is necessary.

XVI. Appendix 8-A: Reproductive Toxins List

The following list comes from the State of California, which by law requires the Governor to revise and republish at least annually the list of chemicals known by the State to cause reproductive toxicity and cancer, commonly known as the Proposition 65 list. Listed below are the substances from the Proposition 65 list that exhibit fetal development toxicity or female/male reproductive toxicity. The date of listing is in the right-hand column.

Reproductive Toxins Table
Chemical Type of Toxicity Listing Mechanism CAS No. Date Listed NSRL or MADL (μg/day)a
A-alpha-C (2-Amino-9H-pyrido[2,3- b]indole) cancer AB 26148-68-5 1-Jan-90 2
Acetaldehyde cancer SQE 75-07-0 1-Apr-88 90
(inhalation)
Acetamide cancer AB 60-35-5 1-Jan-90 10
Acetazolamide developmental FR 59-66-5 20-Aug-99  
Acetochlor cancer SQE 34256-82-1 1-Jan-89  
Acetohydroxamic acid developmental FR 546-88-3 1-Apr-90  
2-Acetylaminofluorene cancer SQE 53-96-3 1-Jul-87 0.2
Acifluorfen sodium cancer AB 62476-59-9 1-Jan-90  
Acrylamide cancer AB 79-06-1 1-Jan-90 0.2
Acrylamide developmental, male AB 79-06-1 25-Feb-11 140
Acrylonitrile cancer FR 107-13-1 1-Jul-87 0.7
Actinomycin D [Basis for listing changed effective February 22, 2013] cancer FR 50-76-0 1-Oct-89 0.00008
Actinomycin D developmental FR 50-76-0 1-Oct-92  
AF-2;[2-(2-furyl)-3-(5-nitro-2- furyl)]acrylamide cancer SQE 3688-53-7 1-Jul-87 3
Aflatoxins cancer SQE --- 1-Jan-88  
Alachlor cancer SQE 15972-60-8 1-Jan-89  
Alcoholic beverages, when associated with alcohol abuse cancer SQE --- 1-Jul-88  
Aldrin cancer SQE 309-00-2 1-Jul-88 0.04
All-trans retinoic acid developmental SQE 302-79-4 1-Jan-89  
Allyl chloride [Delisted October 29, 1999]          
Alprazolam developmental FR 28981-97-7 1-Jul-90  
Altretamine developmental, male FR 645-05-6 20-Aug-99  
Amantadine hydrochloride developmental FR 665-66-7 27-Feb-01  
Amikacin sulfate developmental FR 39831-55-5 1-Jul-90  
2-Aminoanthraquinone cancer LC 117-79-3 1-Oct-89 20
p-Aminoazobenzene cancer AB 60-09-3 1-Jan-90  
o-Aminoazotoluene cancer SQE 97-56-3 1-Jul-87 0.2
4-Aminobiphenyl (4-aminodiphenyl) cancer LC 92-67-1 27-Feb-87 0.03
1-Amino-2,4-dibromoanthraquinone cancer AB 81-49-2 26-Aug-97  
3-Amino-9-ethylcarbazole hydrochloride cancer SQE 6109-97-3 1-Jul-89 9
2-Aminofluorene cancer SQE 153-78-6 29-Jan-99  
Aminoglutethimide developmental FR 125-84-8 1-Jul-90  
Aminoglycosides developmental FR --- 1-Oct-92  
1-Amino-2-methylanthraquinone cancer LC 82-28-0 1-Oct-89 5
2-Amino-5-(5-nitro-2-furyl)-1,3,4- thiadiazole cancer SQE 712-68-5 1-Jul-87 0.04
4-Amino-2-nitrophenol cancer SQE 119-34-6 29-Jan-99  
Aminopterin developmental, female SQE 54-62-6 1-Jul-87  
Amiodarone hydrochloride developmental, female, male FR 19774-82-4 26-Aug-97  
Amitraz developmental AB 33089-61-1 30-Mar-99  
Amitrole cancer SQE 61-82-5 1-Jul-87 0.7
Amoxapine developmental FR 14028-44-5 15-May-98  
Amsacrine cancer LC 51264-14-3 7-Aug-09  
tert-Amyl methyl ether [Delisted December 13, 2013]          
Anabolic steroids female, male FR --- 1-Apr-90  
Analgesic mixtures containing Phenacetin cancer LC --- 27-Feb-87  
Androstenedione cancer AB 63-05-8 3-May-11  
Angiotensin converting enzyme (ACE) inhibitors developmental FR --- 1-Oct-92  
Aniline cancer AB 62-53-3 1-Jan-90 100
Aniline hydrochloride cancer AB 142-04-1 15-May-98  
o-Anisidine cancer SQE 90-04-0 1-Jul-87 5
o-Anisidine hydrochloride cancer SQE 134-29-2 1-Jul-87 7
Anisindione developmental FR 117-37-3 1-Oct-92  
Anthraquinone cancer AB 84-65-1 28-Sep-07  
Antimony oxide (Antimony trioxide) cancer AB 1309-64-4 1-Oct-90  
Aramite cancer SQE 140-57-8 1-Jul-87 20
Areca nut cancer LC --- 3-Feb-06  
Aristolochic acids cancer LC --- 9-Jul-04  
Arsenic (inorganic arsenic compounds) cancer LC -- 27-Feb-87 0.06
(inhalation) 10 (except
inhalation)
Arsenic (inorganic oxides) developmental SQE --- 1-May-97  
Asbestos cancer LC 1332-21-4 27-Feb-87 100
fibers/day (inhalation)
Aspirin (NOTE: It is especially important not to use aspirin during the last three months of pregnancy, unless specifically directed to do so by a physician because it may cause problems in the unborn child or complications during delivery.) developmental, female SQE 50-78-2 1-Jul-90  
Atenolol developmental FR 29122-68-7 26-Aug-97  
Auramine cancer SQE 492-80-8 1-Jul-87 0.8
Auranofin developmental FR 34031-32-8 29-Jan-99  
Avermectin B1 (Abamectin) developmental AB 71751-41-2 3-Dec-10 4.4
Azacitidine cancer AB 320-67-2 1-Jan-92  
Azaserine cancer SQE 115-02-6 1-Jul-87 0.06
Azathioprine cancer LC 446-86-6 27-Feb-87 0.4
Azathioprine developmental FR 446-86-6 1-Sep-96  
Azobenzene cancer AB 103-33-3 1-Jan-90 6
           
Barbiturates developmental FR --- 1-Oct-92  
Beclomethasone dipropionate developmental FR 5534-09-8 15-May-98  
Benomyl developmental, male SQE 17804-35-2 1-Jul-91  
Benthiavalicarb-isopropyl cancer AB 177406-68-7 1-Jul-08  
Benz[a]anthracene cancer SQE 56-55-3 1-Jul-87 0.033 (oral)
Benzene cancer LC 71-43-2 27-Feb-87 6.4 (oral)
13
(inhalation)
Benzene developmental, male SQE 71-43-2 26-Dec-97 (inhalation)
Benzidine [and its salts] cancer LC 92-87-5 27-Feb-87 0.001
Benzidine-based dyes cancer FR --- 1-Oct-92  
Benzodiazepines developmental FR --- 1-Oct-92  
Benzo[b]fluoranthene cancer SQE 205-99-2 1-Jul-87 0.096 (oral)
Benzo[j]fluoranthene cancer SQE 205-82-3 1-Jul-87 0.11 (oral)
Benzo[k]fluoranthene cancer SQE 207-08-9 1-Jul-87  
Benzofuran cancer AB 271-89-6 1-Oct-90 1.1
Benzophenone cancer LC 119-61-9 22-Jun-12  
Benzo[a]pyrene cancer SQE 50-32-8 1-Jul-87 0.06
Benzotrichloride cancer SQE 98-07-7 1-Jul-87  
Benzphetamine hydrochloride developmental FR 5411-22-3 1-Apr-90  
Benzyl chloride cancer AB 100-44-7 1-Jan-90 4
Benzyl violet 4B cancer SQE 1694-09-3 1-Jul-87 30
Beryllium and beryllium compounds cancer SQE --- 1-Oct-87  
Beryllium         0.1
Beryllium oxide         0.1
Beryllium sulfate         0.0002
Betel quid with tobacco cancer AB --- 1-Jan-90  
Betel quid without tobacco cancer LC --- 3-Feb-06  
2,2-Bis(bromomethyl)-1,3-propanediol cancer AB 3296-90-0 1-May-96  
Bis(2-chloroethyl)ether cancer SQE 111-44-4 1-Apr-88 0.3
N,N-Bis(2-chloroethyl)-2-
naphthylamine (Chlornapazine)		 cancer LC 494-03-1 27-Feb-87  
Bischloroethyl nitrosourea (BCNU) (Carmustine) cancer SQE 154-93-8 1-Jul-87  
Bischloroethyl nitrosourea (BCNU) (Carmustine) developmental FR 154-93-8 1-Jul-90  
Bis(chloromethyl)ether cancer LC 542-88-1 27-Feb-87 0.02
Bis(2-chloro-1-methylethyl)ether, technical grade cancer SQE --- 29-Oct-99  
Bisphenol A (BPA) [Delisted April 19, 2013]          
Bitumens, extracts of steam-refined and air refined cancer AB --- 1-Jan-90  
Bracken fern cancer AB --- 1-Jan-90  
Bromacil lithium salt developmental AB 53404-19-6 18-May-99  
Bromacil lithium salt male SQE 53404-19-6 17-Jan-03  
Bromate cancer AB 15541-45-4 31-May-02  
Bromochloroacetic acid cancer AB 5589-96-8 6-Apr-10  
Bromodichloromethane cancer AB 75-27-4 1-Jan-90 5
Bromoethane cancer AB 74-96-4 22-Dec-00 96
Bromoform cancer AB 75-25-2 1-Apr-91 64
1-Bromopropane (1-BP) developmental, female, male AB 106-94-5 7-Dec-04  
2-Bromopropane (2-BP) female, male AB 75-26-3 31-May-05  
Bromoxynil developmental FR 1689-84-5 1-Oct-90  
Bromoxynil octanoate developmental AB 1689-99-2 18-May-99  
Butabarbital sodium developmental FR 143-81-7 1-Oct-92  
1,3-Butadiene cancer SQE 106-99-0 1-Apr-88 0.4
1,3-Butadiene developmental, female, male AB 106-99-0 16-Apr-04  
1,4-Butanediol dimethanesulfonate (Busulfan) cancer LC 55-98-1 27-Feb-87  
1,4-Butanediol dimethanesulfonate (Busulfan) developmental SQE 55-98-1 1-Jan-89  
Butylated hydroxyanisole cancer AB 25013-16-5 1-Jan-90 4000
Butyl benzyl phthalate (BBP)d developmental AB 85-68-7 2-Dec-05 1200 (oral)
n-Butyl glycidyl ether [Delisted April 4, 2014]          
beta-Butyrolactone cancer SQE 3068-88-0 1-Jul-87 0.7
           
Cacodylic acid cancer AB 75-60-5 1-May-96  
Cadmium developmental, male SQE --- 1-May-97 4.1 (oral)
Cadmium and cadmium compounds cancer SQE --- 1-Oct-87  
Cadmium         0.05
(inhalation)
Caffeic acid cancer AB 331-39-5 1-Oct-94  
Captafol cancer SQE 2425-06-1 1-Oct-88 5
Captan cancer AB 133-06-2 1-Jan-90 300
Carbamazepine developmental FR 298-46-4 29-Jan-99  
Carbaryl cancer AB 63-25-2 5-Feb-10  
Carbaryl [Basis for listing changed effective December 27, 2013] developmental, female, male AB 63-25-2 7-Aug-09  
Carbazole cancer AB 86-74-8 1-May-96 4.1
Carbon black (airborne, unbound particles of respirable size) cancer AB 1333-86-4 21-Feb-03  
Carbon disulfide developmental, female, male SQE 75-15-0 1-Jul-89  
Carbon monoxide developmental SQE 630-08-0 1-Jul-89  
Carbon tetrachloride cancer SQE 56-23-5 1-Oct-87 5
Carbon-black extracts cancer AB --- 1-Jan-90  
Carboplatin developmental FR 41575-94-4 1-Jul-90  
N-Carboxymethyl-N-nitrosourea cancer SQE 60391-92-6 25-Jan-02 0.7
Catechol cancer AB 120-80-9 15-Jul-03  
Ceramic fibers (airborne particles of respirable size) cancer AB --- 1-Jul-90  
Certain combined chemotherapy for lymphomas cancer LC --- 27-Feb-87  
Chenodiol developmental FR 474-25-9 1-Apr-90  
Chloral cancer LC 75-87-6 13-Sep-13  
Chloral hydrate cancer LC 302-17-0 13-Sep-13  
Chlorambucil cancer LC 305-03-3 27-Feb-87 0.002
Chlorambucil developmental SQE 305-03-3 1-Jan-89  
Chloramphenicol [Delisted January 4, 2013]          
Chloramphenicol sodium succinate cancer FR 982-57-0 27-Sep-13  
Chlorcyclizine hydrochloride developmental FR 1620-21-9 1-Jul-87  
Chlordane cancer SQE 57-74-9 1-Jul-88 0.5
Chlordecone (Kepone) cancer SQE 143-50-0 1-Jan-88 0.04
Chlordecone (Kepone) developmental SQE 143-50-0 1-Jan-89  
Chlordiazepoxide developmental FR 58-25-3 1-Jan-92  
Chlordiazepoxide hydrochloride developmental FR 438-41-5 1-Jan-92  
Chlordimeform cancer SQE 6164-98-3 1-Jan-89  
Chlorendic acid cancer SQE 115-28-6 1-Jul-89 8
Chlorinated paraffins (Average chain length, C12;approximately 60 percent chlorine by weight) cancer SQE 108171-26-2 1-Jul-89 8
p-Chloroaniline cancer AB 106-47-8 1-Oct-94 1.5
p-Chloroaniline hydrochloride cancer AB 20265-96-7 15-May-98 1.9
Chlorodibromomethane [Delisted October 29, 1999]          
Chloroethane (Ethyl chloride) cancer AB 75-00-3 1-Jul-90 150
1-(2-Chloroethyl)-3-cyclohexyl-1- nitrosourea (CCNU) (Lomustine) cancer SQE 13010-47-4 1-Jan-88  
1-(2-Chloroethyl)-3-cyclohexyl-1- nitrosourea (CCNU) (Lomustine) developmental FR 13010-47-4 1-Jul-90  
1-(2-Chloroethyl)-3-(4- methylcyclohexyl)-1-nitrosourea
(Methyl-CCNU)		 cancer SQE 13909-09-6 1-Oct-88  
Chloroform cancer SQE 67-66-3 1-Oct-87 20 (oral)
40
(inhalation)
Chloroform developmental LC 67-66-3 7-Aug-09  
Chloromethyl methyl ether (technical grade) cancer LC 107-30-2 27-Feb-87 0.3
3-Chloro-2-methylpropene cancer SQE 563-47-3 1-Jul-89 5
1-Chloro-4-nitrobenzene cancer SQE 100-00-5 29-Oct-99  
4-Chloro-o-phenylenediamine cancer SQE 95-83-0 1-Jan-88 40
Chloroprene cancer AB 126-99-8 2-Jun-00  
2-Chloropropionic acid [Basis for listing changed effective December 20, 2013] male SQE 598-78-7 7-Aug-09  
Chlorothalonil cancer SQE 1897-45-6 1-Jan-89 41
p-Chloro-o-toluidine cancer AB 95-69-2 1-Jan-90 3
p-Chloro-o-toluidine, strong acid salts of cancer AB --- 15-May-98  
p-Chloro-o-toluidine, hydrochloride         3.3
5-Chloro-o-toluidine and its strong acid salts cancer SQE --- 24-Oct-97  
Chlorotrianisene cancer FR 569-57-3 1-Sep-96  
Chlorozotocin cancer AB 54749-90-5 1-Jan-92 0.003
Chlorsulfuron [Delisted June 6, 2014]       14-May-99  
Chromium (hexavalent compounds) cancer LC --- 27-Feb-87 0.001
(inhalation)
Chromium (hexavalent compounds) developmental, female, male SQE --- 19-Dec-08 8.2 (oral)
Chrysene cancer AB 218-01-9 1-Jan-90 0.35 (oral)
C.I. Acid Red 114 cancer AB 6459-94-5 1-Jul-92  
C.I. Basic Red 9 monohydrochloride cancer SQE 569-61-9 1-Jul-89 3
C.I. Direct Blue 15 cancer AB 2429-74-5 26-Aug-97  
C.I. Direct Blue 218 cancer AB 28407-37-6 26-Aug-97 50
C.I. Disperse Yellow 3 cancer SQE 2832-40-8 8-Feb-13  
C.I. Solvent Yellow 14 cancer AB 842-07-9 15-May-98  
Ciclosporin (Cyclosporin A; Cyclosporine) cancer AB 59865-13-3;
79217-60-0		 1-Jan-92  
Cidofovir cancer, developmental, female, male FR 113852-37-2 29-Jan-99  
Cinnamyl anthranilate cancer SQE 87-29-6 1-Jul-89 200
Cisplatin cancer SQE 15663-27-1 1-Oct-88  
Citrus Red No. 2 cancer LC 6358-53-8 1-Oct-89  
Cladribine developmental FR 4291-63-8 1-Sep-96  
Clarithromycin developmental FR 81103-11-9 1-May-97  
Clobetasol propionate developmental,
female		 FR 25122-46-7 15-May-98  
Clofibrate cancer FR 637-07-0 1-Sep-96  
Clomiphene citrate cancer FR 50-41-9 24-May-13  
Clomiphene citrate developmental FR 50-41-9 1-Apr-90  
Clorazepate dipotassium developmental FR 57109-90-7 1-Oct-92  
Cobalt metal powder cancer AB 7440-48-4 1-Jul-92  
Cobalt [II] oxide cancer AB 1307-96-6 1-Jul-92  
Cobalt sulfate cancer LC 10124-43-3 20-May-05  
Cobalt sulfate heptahydrate cancer AB 10026-24-1 2-Jun-00  
Cocaine developmental,
female		 SQE 50-36-2 1-Jul-89  
Coconut oil diethanolamine condensate (cocamide diethanolamine) cancer LC 68603-42-9 22-Jun-12  
Codeine phosphate developmental FR 52-28-8 15-May-98  
Coke oven emissions cancer LC --- 27-Feb-87 0.3
Colchicine developmental, male FR 64-86-8 1-Oct-92  
Conjugated estrogens cancer LC --- 27-Feb-87  
Conjugated estrogens developmental FR --- 1-Apr-90  
Creosotes cancer SQE --- 1-Oct-88  
p-Cresidine cancer SQE 120-71-8 1-Jan-88 5
Cumene cancer AB 98-82-8 6-Apr-10  
Cupferron cancer SQE 135-20-6 1-Jan-88 3
Cyanazine developmental FR 21725-46-2 1-Apr-90  
Cycasin cancer SQE 14901-08-7 1-Jan-88  
Cycloate developmental AB 1134-23-2 19-Mar-99  
Cyclohexanol [Delisted January 25, 2002]          
Cycloheximide developmental FR 66-81-9 1-Jan-89  
Cyclopenta[cd]pyrene cancer LC 27208-37-3 29-Apr-11  
Cyclophosphamide (anhydrous) cancer LC 50-18-0 27-Feb-87 1
Cyclophosphamide (anhydrous) developmental, female, male SQE -
development al FR - female, male		 50-18-0 1-Jan-89  
Cyclophosphamide (hydrated) cancer LC 6055-19-2 27-Feb-87 1
Cyclophosphamide (hydrated) developmental, female, male SQE -
development alFR - female, male		 6055-19-2 1-Jan-89  
Cyhexatin developmental FR 13121-70-5 1-Jan-89  
Cytarabine developmental SQE 147-94-4 1-Jan-89  
Cytembena cancer AB 21739-91-3 15-May-98  
           
D&C Orange No. 17 cancer AB 3468-63-1 1-Jul-90  
D&C Red No. 8 cancer AB 2092-56-0 1-Oct-90  
D&C Red No. 9 cancer AB 5160-02-1 1-Jul-90 100
D&C Red No. 19 cancer AB 81-88-9 1-Jul-90  
Dacarbazine cancer SQE 4342-03-4 1-Jan-88 0.01
Dacarbazine developmental FR 4342-03-4 29-Jan-99  
Daminozide cancer AB 1596-84-5 1-Jan-90 40
Danazol developmental FR 17230-88-5 1-Apr-90  
Dantron (Chrysazin; 1,8- Dihydroxyanthraquinone) cancer AB 117-10-2 1-Jan-92 9
Daunomycin cancer SQE 20830-81-3 1-Jan-88  
Daunorubicin hydrochloride developmental FR 23541-50-6 1-Jul-90  
2,4-D butyric acid [Basis for the removal of developmental endpoint effective June 22, 2001] male AB 94-82-6 18-Jun-99 910
DDD (Dichlorodiphenyl- dichloroethane) cancer SQE 72-54-8 1-Jan-89 2 (DDT, DDE, DDD in combinatio n)
DDE (Dichlorodiphenyl- dichloroethylene) cancer SQE 72-55-9 1-Jan-89 2 (DDT, DDE, DDD in combinatio
DDT (Dichlorodiphenyl- trichloroethane) cancer SQE 50-29-3 1-Oct-87 2 (DDT, DDE, DDD in combination)
o,p'-DDT developmental, female, male AB 789-02-6 15-May-98  
p,p'-DDT developmental, female, male AB 50-29-3 15-May-98  
DDVP (Dichlorvos) cancer SQE 62-73-7 1-Jan-89 2
2,4-DP (dichloroprop) [Delisted January 25, 2002]          
Demeclocycline hydrochloride (internal use) developmental FR 64-73-3 1-Jan-92  
N,N'-Diacetylbenzidine cancer LC 613-35-4 1-Oct-89  
2,4-Diaminoanisole cancer FR 615-05-4 1-Oct-90 30
2,4-Diaminoanisole sulfate cancer SQE 39156-41-7 1-Jan-88 50
4,4'-Diaminodiphenyl ether (4,4'- Oxydianiline) cancer SQE 101-80-4 1-Jan-88 5
2,4-Diaminotoluene cancer SQE 95-80-7 1-Jan-88 0.2
Diaminotoluene (mixed) cancer AB --- 1-Jan-90  
Diazepam developmental FR 439-14-5 1-Jan-92  
Diazoaminobenzene cancer LC 136-35-6 20-May-05  
Diazoxide developmental FR 364-98-7 27-Feb-01  
Dibenz[a,h]acridine cancer SQE 226-36-8 1-Jan-88  
Dibenz[a,j]acridine cancer SQE 224-42-0 1-Jan-88  
Dibenz[a,h]anthracene cancer SQE 53-70-3 1-Jan-88 0.2
7H-Dibenzo[c,g]carbazole cancer SQE 194-59-2 1-Jan-88 0.0030
(oral)
Dibenzo[a,e]pyrene cancer SQE 192-65-4 1-Jan-88  
Dibenzo[a,h]pyrene cancer SQE 189-64-0 1-Jan-88 0.0054
(oral)
Dibenzo[a,i]pyrene cancer SQE 189-55-9 1-Jan-88 0.0050
(oral)
Dibenzo[a,l]pyrene cancer SQE 191-30-0 1-Jan-88  
Dibromoacetic acid cancer AB 631-64-1 17-Jun-08  
Dibromoacetonitrile cancer AB 3252-43-5 3-May-11  
1,2-Dibromo-3-chloropropane (DBCP) cancer FR 96-12-8 1-Jul-87 0.1
1,2-Dibromo-3-chloropropane (DBCP)
[Basis for listing changed effective November 22, 2013]		 male FR 96-12-8 27-Feb-87 3.1 (oral)
4.3 (inhalation)
2,3-Dibromo-1-propanol cancer AB 96-13-9 1-Oct-94  
Dichloroacetic acid cancer AB 79-43-6 1-May-96  
Dichloroacetic acid developmental, male AB 79-43-6 7-Aug-09  
p-Dichlorobenzene cancer SQE 106-46-7 1-Jan-89 20
3,3'-Dichlorobenzidine cancer SQE 91-94-1 1-Oct-87 0.6
3,3'-Dichlorobenzidine dihydrochloride cancer AB 612-83-9 15-May-98  
1,1-Dichloro-2,2-bis(p- chloropheny)ethylene (DDE) developmental, male AB 72-55-9 30-Mar-10  
1,4-Dichloro-2-butene cancer AB 764-41-0 1-Jan-90  
3,3'-Dichloro-4,4'-diamino-diphenyl ether cancer SQE 28434-86-8 1-Jan-88  
1,1-Dichloroethane cancer AB 75-34-3 1-Jan-90 100
Dichloromethane (Methylene chloride) cancer SQE 75-09-2 1-Apr-88 50
200
(inhalation)
Dichlorophene developmental AB 97-23-4 27-Apr-99  
Dichlorphenamide developmental FR 120-97-8 27-Feb-01  
1,2-Dichloropropane cancer AB 78-87-5 1-Jan-90 9.7
1,3-Dichloro-2-propanol (1,3-DCP) cancer SQE 96-23-1 8-Oct-10  
1,3-Dichloropropene cancer SQE 542-75-6 1-Jan-89  
Diclofop-methyl cancer AB 51338-27-3 6-Apr-10  
Diclofop methyl developmental AB 51338-27-3 5-Mar-99  
Dicumarol developmental FR 66-76-2 1-Oct-92  
Dieldrin cancer SQE 60-57-1 1-Jul-88 0.04
Dienestrol [Delisted January 4, 2013]          
Diepoxybutane cancer SQE 1464-53-5 1-Jan-88  
Diesel engine exhaust cancer AB --- 1-Oct-90  
Diethanolamine cancer LC 111-42-2 22-Jun-12  
Di(2-ethylhexyl)phthalate cancer SQE 117-81-7 1-Jan-88 310
Di(2-ethylhexyl)phthalate developmental, male AB 117-81-7 24-Oct-03  
Adultb   -     4200 (intravenou s)
Infant boys, age 29 days to 24 monthsb   -     600 (intravenou s)
Neonatal infant boys, age 0 to 28 daysb   -     210 (intravenous)
Adultb   -     410 (oral)
Infant boys, age 29 days to 24 monthsb   -     58 (oral)
Neonatal infant boys, age 0 to 28 daysb   -     20 (oral)
1,2-Diethylhydrazine cancer SQE 1615-80-1 1-Jan-88  
Diethylstilbestrol (DES) cancer LC 56-53-1 27-Feb-87 0.002
Diethylstilbestrol (DES) developmental FR 56-53-1 1-Jul-87  
Diethyl sulfate cancer SQE 64-67-5 1-Jan-88  
Diflunisal developmental, female FR 22494-42-4 29-Jan-99  
Diglycidyl ether [Delisted April 4, 2014]          
Diglycidyl resorcinol ether (DGRE) cancer SQE 101-90-6 1-Jul-89 0.4
Dihydroergotamine mesylate developmental FR 6190-39-2 1-May-97  
Dihydrosafrole cancer SQE 94-58-6 1-Jan-88 20
Diisononyl phthalate (DINP) cancer SQE --- 20-Dec-13  
Diisopropyl sulfate cancer AB 2973-10-6 1-Apr-93  
      68515-49-1/    
Di-isodecyl phthalate (DIDP) developmental AB 26761-40-0 20-Apr-07 2200
Diltiazem hydrochloride developmental FR 33286-22-5 27-Feb-01  
3,3'-Dimethoxybenzidine (o- Dianisidine) cancer SQE 119-90-4 1-Jan-88 0.15
3,3'-Dimethoxybenzidine dihydrochloride cancer AB 20325-40-0 1-Oct-90 0.19
3,3'-Dimethoxybenzidine-based dyes metabolized to 3,3'-dimethoxybenzidine cancer AB --- 11-Jun-04  
N,N-Dimethylacetamide [Basis for addition of male reproductive endpoint effective December 20, 2013] developmental, male SQE 127-19-5 21-May-10  
4-Dimethylaminoazobenzene cancer SQE 60-11-7 1-Jan-88 0.2
trans-2-
[(Dimethylamino)methylimino]-5-[2-(5- nitro-2-furyl)vinyl]-1,3,4-oxadiazole		 cancer SQE 55738-54-0 1-Jan-88 2
7,12-Dimethylbenz(a)anthracene cancer AB 57-97-6 1-Jan-90 0.003
3,3'-Dimethylbenzidine (ortho-Tolidine) cancer SQE 119-93-7 1-Jan-88 0.044
3,3'-Dimethylbenzidine dihydrochloride cancer AB 612-82-8 1-Apr-92 0.059
3,3'-Dimethylbenzidine-based dyes metabolized to 3,3'-dimethylbenzidine cancer AB --- 11-Jun-04  
Dimethylcarbamoyl chloride cancer SQE 79-44-7 1-Jan-88 0.05
1,1-Dimethylhydrazine (UDMH) cancer LC 57-14-7 1-Oct-89  
1,2-Dimethylhydrazine cancer SQE 540-73-8 1-Jan-88 0.001
2,6-Dimethyl-N-nitrosomorpholine (DMNM) cancer SQE 1456-28-6 8-Feb-13  
Dimethyl sulfate cancer SQE 77-78-1 1-Jan-88  
N,N-Dimethyl-p-toluidine cancer AB 99-97-8 2-May-14  
Dimethylvinylchloride cancer SQE 513-37-1 1-Jul-89 20
Di-n-butyl phthalate (DBP) developmental, female, male AB 84-74-2 2-Dec-05 8.7
Di-n-hexyl phthalate (DnHP) female, male AB 84-75-3 2-Dec-05 2200 (oral)
m-Dinitrobenzene male AB 99-65-0 1-Jul-90 38
o-Dinitrobenzene male AB 528-29-0 1-Jul-90  
p-Dinitrobenzene male AB 100-25-4 1-Jul-90  
3,7-Dinitrofluoranthene cancer AB 105735-71-5 26-Aug-97  
3,9-Dinitrofluoranthene cancer AB 22506-53-2 26-Aug-97  
1,3-Dinitropyrene cancer LC 75321-20-9 2-Nov-12  
1,6-Dinitropyrene cancer AB 42397-64-8 1-Oct-90  
1,8-Dinitropyrene cancer AB 42397-65-9 1-Oct-90  
2,4-Dinitrotoluene cancer SQE 121-14-2 1-Jul-88 2
2,4-Dinitrotoluene male AB 121-14-2 20-Aug-99  
2,6-Dinitrotoluene cancer SQE 606-20-2 1-Jul-95  
2,6-Dinitrotoluene male AB 606-20-2 20-Aug-99  
Dinitrotoluene (technical grade) female, male AB --- 20-Aug-99  
Dinitrotoluene mixture, 2,4-/2,6- cancer AB --- 1-May-96  
Dinocap developmental FR 39300-45-3 1-Apr-90  
Dinoseb developmental,
male		 FR 88-85-7 1-Jan-89  
Di-n-propyl isocinchomeronate (MGK Repellent 326) cancer AB 136-45-8 1-May-96  
1,4-Dioxane cancer SQE 123-91-1 1-Jan-88 30
Diphenylhydantoin (Phenytoin) cancer SQE 57-41-0 1-Jan-88  
Diphenylhydantoin (Phenytoin) developmental SQE 57-41-0 1-Jul-87  
Diphenylhydantoin (Phenytoin), sodium salt cancer SQE 630-93-3 1-Jan-88  
Direct Black 38 (technical grade) cancer SQE 1937-37-7 1-Jan-88 0.09
Direct Blue 6 (technical grade) cancer SQE 2602-46-2 1-Jan-88 0.09
Direct Brown 95 (technical grade) cancer SQE 16071-86-6 1-Oct-88 0.1
Disodium cyanodithioimidocarbonate developmental AB 138-93-2 30-Mar-99 56 (oral)
170 (oral) as 32%
pesticidal formulation
Disperse Blue 1 cancer AB 2475-45-8 1-Oct-90 200
Diuron cancer AB 330-54-1 31-May-02  
Doxorubicin hydrochloride (Adriamycin) cancer SQE 25316-40-9 1-Jul-87  
Doxorubicin hydrochloride (Adriamycin) developmental, male FR 25316-40-9 29-Jan-99  
Doxycycline (internal use) developmental FR 564-25-0 1-Jul-90  
Doxycycline calcium (internal use) developmental FR 94088-85-4 1-Jan-92  
Doxycycline hyclate (internal use) developmental FR 24390-14-5 1-Oct-91  
Doxycycline monohydrate (internal use) developmental FR 17086-28-1 1-Oct-91  
Emissions from combustion of coal cancer AB --- 7-Aug-13  
Emissions from high-temperature unrefined rapeseed oil cancer AB --- 3-Jan-14  
Endrin developmental AB 72-20-8 15-May-98  
Environmental tobacco smoke (ETS) developmental SQE --- 9-Jun-06  
Epichlorohydrin cancer SQE 106-89-8 1-Oct-87 9
Epichlorohydrin male AB 106-89-8 1-Sep-96  
Epoxiconazole cancer AB 135319-73-2 15-Apr-11  
Ergotamine tartrate developmental FR 379-79-3 1-Apr-90  
Erionite cancer SQE 12510-42-8;
66733-21-9		 1-Oct-88  
Estradiol 17B cancer SQE 50-28-2 1-Jan-88 0.02
Estragole cancer SQE 140-67-0 29-Oct-99  
Estrogens, steroidal cancer LC --- 19-Aug-05  
Estrogen-progestogen (combined) used as menopausal therapy cancer LC --- 4-Nov-11  
Estrone cancer SQE 53-16-7 1-Jan-88  
Estropipate cancer, developmental FR 7280-37-7 26-Aug-97  
Ethanol in alcoholic beverages cancer LC --- 29-Apr-11  
Ethinylestradiol cancer SQE 57-63-6 1-Jan-88  
Ethionamide developmental FR 536-33-4 26-Aug-97  
Ethoprop cancer AB 13194-48-4 27-Feb-01  
Ethyl acrylate cancer SQE 140-88-5 1-Jul-89  
Ethyl alcohol in alcoholic beverages developmental SQE --- 1-Oct-87  
Ethylbenzene cancer AB 100-41-4 11-Jun-04 54
(inhalation) 41 (oral)
Ethyl-tert-butyl ether [Delisted December 13, 2013]          
Ethyl dipropylthiocarbamate developmental AB 759-94-4 27-Apr-99 700 (oral
and inhalation)
6700
(dermal)
Ethyl-4,4'-dichlorobenzilate cancer AB 510-15-6 1-Jan-90 7
Ethylene dibromide cancer FR 106-93-4 1-Jul-87 0.2 (oral)
3
(inhalation)
Ethylene dibromide developmental, male AB 106-93-4 15-May-98  
Ethylene dichloride (1,2- Dichloroethane) cancer SQE 107-06-2 1-Oct-87 10
Ethylene glycol monoethyl ether developmental, male SQE 110-80-5 1-Jan-89 750 (oral)
960 (inhalation)
Ethylene glycol monoethyl ether acetate developmental, male AB 111-15-9 1-Jan-93 1100 (oral)
1400 (inhalation)
Ethylene glycol monomethyl ether developmental,
male		 SQE 109-86-4 1-Jan-89 63 (oral)
Ethylene glycol monomethyl ether acetate developmental, male AB 110-49-6 1-Jan-93 98 (oral)
Ethyleneimine cancer SQE 151-56-4 1-Jan-88 0.01
Ethylene oxide cancer FR 75-21-8 1-Jul-87 2
Ethylene oxide [Basis for listing changed effective November 22, 2013] female FR 75-21-8 27-Feb-87 20
Ethylene oxide [Basis for listing changed effective November 22, 2013] developmental, male FR 75-21-8 7-Aug-09  
Ethylene thiourea cancer AB 96-45-7 1-Jan-88 20
Ethylene thiourea developmental SQE 96-45-7 1-Jan-93  
2-Ethylhexanoic acid [Delisted December 13, 2013]          
Ethyl methanesulfonate cancer SQE 62-50-0 1-Jan-88  
Etodolac developmental, female FR 41340-25-4 20-Aug-99  
Etoposide cancer LC 33419-42-0 4-Nov-11  
Etoposide developmental FR 33419-42-0 1-Jul-90  
Etoposide in combination with cisplatin and bleomycin cancer LC --- 4-Nov-11  
Etretinate developmental SQE 54350-48-0 1-Jul-87  
Fenoxaprop ethyl developmental AB 66441-23-4 26-Mar-99  
Fenoxycarb cancer AB 72490-01-8 2-Jun-00  
Filgrastim developmental FR 121181-53-1 27-Feb-01  
Fluazifop butyl developmental AB 69806-50-4 6-Nov-98  
Flunisolide developmental, female FR 3385-03-3 15-May-98  
Fluorouracil developmental SQE 51-21-8 1-Jan-89  
Fluoxymesterone developmental FR 76-43-7 1-Apr-90  
Flurazepam hydrochloride developmental FR 1172-18-5 1-Oct-92  
Flurbiprofen developmental,
female		 FR 5104-49-4 20-Aug-99  
Flutamide developmental FR 13311-84-7 1-Jul-90  
Fluticasone propionate developmental FR 80474-14-2 15-May-98  
Fluvalinate developmental AB 69409-94-5 6-Nov-98  
Folpet cancer SQE 133-07-3 1-Jan-89 200
Formaldehyde (gas) cancer SQE 50-00-0 1-Jan-88 40
2-(2-Formylhydrazino)-4-(5-nitro-2- furyl)thiazole cancer SQE 3570-75-0 1-Jan-88 0.3
Fumonisin B1 cancer AB 116355-83-0 14-Nov-03  
Furan cancer AB 110-00-9 1-Oct-93  
Furazolidone cancer AB 67-45-8 1-Jan-90  
Furmecyclox cancer AB 60568-05-0 1-Jan-90 20
Fusarin C cancer SQE 79748-81-5 1-Jul-95  
Gallium arsenide cancer LC 1303-00-0 1-Aug-08  
Ganciclovir cancer,
developmental, male		 FR 82410-32-0 26-Aug-97  
Ganciclovir sodium developmental, male FR 107910-75-8 26-Aug-97  
Gasoline engine exhaust (condensates/extracts) cancer AB --- 1-Oct-90  
Gemfibrozil cancer FR 25812-30-0 22-Dec-00  
Gemfibrozil female, male FR 25812-30-0 20-Aug-99  
Glass wool fibers (inhalable and biopersistent) cancer AB --- 1-Jul-90  
Glu-P-1 (2-Amino-6- methyldipyrido[1,2- a:3',2'-d]imidazole) cancer AB 67730-11-4 1-Jan-90 0.1
Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'- d]imidazole) cancer AB 67730-10-3 1-Jan-90 0.5
Glycidaldehyde cancer SQE 765-34-4 1-Jan-88  
Glycidol cancer AB 556-52-5 1-Jul-90 0.54
Goserelin acetate developmental, female, male FR 65807-02-5 26-Aug-97  
Griseofulvin cancer AB 126-07-8 1-Jan-90  
Gyromitrin (Acetaldehyde methylformylhydrazone) cancer SQE 16568-02-8 1-Jan-88 0.07
Halazepam developmental FR 23092-17-3 1-Jul-90  
Halobetasol propionate developmental FR 66852-54-8 20-Aug-99  
Haloperidol developmental, female FR 52-86-8 29-Jan-99  
Halothane developmental FR 151-67-7 1-Sep-96  
HC Blue 1 cancer SQE 2784-94-3 1-Jul-89 10
Heptachlor cancer SQE 76-44-8 1-Jul-88 0.2
Heptachlor developmental AB 76-44-8 20-Aug-99  
Heptachlor epoxide cancer SQE 1024-57-3 1-Jul-88 0.08
Herbal remedies containing plant species of the genus Aristolochia cancer LC --- 9-Jul-04  
Hexachlorobenzene cancer SQE 118-74-1 1-Oct-87 0.4
Hexachlorobenzene developmental SQE 118-74-1 1-Jan-89  
Hexachlorobutadiene cancer AB 87-68-3 3-May-11  
Hexachlorocyclohexane (technical grade) cancer SQE --- 1-Oct-87 0.2
Hexachlorocyclohexane (alpha isomer)         0.3
Hexachlorocyclohexane (beta isomer)         0.5
Hexachlorocyclohexane (gamma isomer)         0.6
Hexachlorodibenzodioxin cancer SQE 34465-46- 8 1-Apr-88 0.0002
Hexachloroethane cancer AB 67-72-1 1-Jul-90 20
2,4-Hexadienal (89% trans, trans isomer; 11% cis, trans isomer) cancer AB --- 4-Mar-05  
Hexafluoroacetone [Basis for listing changed effective June 6, 2014] developmental, male SQE 684-16-2 1-Aug-08  
Hexamethylphosphoramide cancer SQE 680-31-9 1-Jan-88  
Hexamethylphosphoramide male AB 680-31-9 1-Oct-94  
Histrelin acetate developmental FR --- 15-May-98  
Hydramethylnon developmental, male AB 67485-29-4 5-Mar-99 120 (oral)
Hydrazine cancer SQE 302-01-2 1-Jan-88 0.04
Hydrazine sulfate cancer SQE 10034-93-2 1-Jan-88 0.2
Hydrazobenzene (1,2- Diphenylhydrazine) cancer SQE 122-66-7 1-Jan-88 0.8
Hydrogen cyanide (HCN) and cyanide salts (CN salts) male AB --- 5-Jul-13  
Cyanide salts that readily dissociate in solution (expressed as cyanide)f         9.8
Hydrogen cyanidef         10 (oral)
Sodium cyanidef         19 (oral)
Potassium cyanidef         25 (oral)
1-Hydroxyanthraquinone cancer LC 129-43-1 27-May-05  
Hydroxyurea developmental FR 127-07-1 1-May-97  
Idarubicin hydrochloride developmental, male FR 57852-57-0 20-Aug-99  
Ifosfamide developmental FR 3778-73-2 1-Jul-90  
Iodine-131 developmental SQE 10043-66-0 1-Jan-89  
Imazalil cancer AB 35554-44-0 20-May-11 11
Indeno [1,2,3-cd]pyrene cancer SQE 193-39-5 1-Jan-88  
Indium phosphide cancer AB 22398-80-7 27-Feb-01  
IQ (2-Amino-3-methylimidazo[4,5-f] quinoline) cancer AB 76180-96-6 1-Apr-90 0.5
Iprodione cancer AB 36734-19-7 1-May-96  
Iprovalicarb cancer AB 140923-17-7/
140923-25-7		 1-Jun-07  
Iron dextran complex cancer SQE 9004-66-4 1-Jan-88  
Isobutyl nitrite cancer AB 542-56-3 1-May-96 7.4
Isoprene cancer AB 78-79-5 1-May-96  
Isopyrazam cancer AB 881685-58-1 24-Jul-12  
Isosafrole [Delisted December 8, 2006]          
Isotretinoin developmental SQE 4759-48-2 1-Jul-87  
Isoxaflutole cancer AB 141112-29-0 22-Dec-00  
Kresoxim-methyl cancer AB 143390-89-0 3-Feb-12  
Lactofen cancer SQE 77501-63-4 1-Jan-89  
Lasiocarpine cancer SQE 303-34-4 1-Apr-88 0.09
Lead [Basis for listing changed effective November 22, 2013] developmental, female, male FR --- 27-Feb-87 0.5
Lead and lead compounds cancer AB --- 1-Oct-92  
Lead         15 (oral)
Lead acetate cancer SQE 301-04-2 1-Jan-88 23 (oral)
Lead phosphate cancer SQE 7446-27-7 1-Apr-88 58 (oral)
Lead subacetate cancer LC 1335-32-6 1-Oct-89 41 (oral)
Leather dust cancer LC --- 29-Apr-11  
Leuprolide acetate developmental, female, male FR 74381-53-6 26-Aug-97  
Levodopa developmental FR 59-92-7 29-Jan-99  
Levonorgestrel implants female FR 797-63-7 15-May-98  
Lindane and other hexachlorocyclohexane isomers cancer LC --- 1-Oct-89  
Linuron developmental AB 330-55-2 19-Mar-99 460
Lithium carbonate developmental FR 554-13-2 1-Jan-91  
Lithium citrate developmental FR 919-16-4 1-Jan-91  
Lorazepam developmental FR 846-49-1 1-Jul-90  
Lovastatin developmental FR 75330-75-5 1-Oct-92  
Lynestrenol cancer AB 52-76-6 27-Feb-01  
Malonaldehyde, sodium salt cancer AB 24382-04-5 29-Apr-11  
Mancozeb cancer AB 8018-01-7 1-Jan-90  
Maneb cancer AB 12427-38-2 1-Jan-90  
Marijuana smoke cancer SQE --- 19-Jun-09  
Me-A-alpha-C (2-Amino-3-methyl-9H- pyrido[2,3-b]indole) cancer AB 68006-83-7 1-Jan-90 0.6
Mebendazole developmental FR 31431-39-7 20-Aug-99  
Medroxyprogesterone acetate cancer AB 71-58-9 1-Jan-90  
Medroxyprogesterone acetate developmental FR 71-58-9 1-Apr-90  
Megestrol acetate cancer FR 595-33-5 28-Mar-14  
Megestrol acetate developmental FR 595-33-5 1-Jan-91  
MeIQ (2-Amino-3,4-dimethylimidazo[4,5-f]quinoline) cancer AB 77094-11-2 1-Oct-94 0.46
MeIQx (2-Amino-3,8- dimethylimidazo[4,5-f]quinoxaline) cancer AB 77500-04-0 1-Oct-94 0.41
Melphalan cancer LC 148-82-3 27-Feb-87 0.005
Melphalan developmental FR 148-82-3 1-Jul-90  
Menotropins developmental FR 9002-68-0 1-Apr-90  
Mepanipyrim cancer AB 110235-47-7 1-Jul-08  
Meprobamate developmental FR 57-53-4 1-Jan-92  
Mercaptopurine developmental FR 6112-76-1 1-Jul-90  
Mercury and mercury compounds developmental AB --- 1-Jul-90  
Merphalan cancer SQE 531-76-0 1-Apr-88  
Mestranol cancer SQE 72-33-3 1-Apr-88  
Metam potassium cancer AB 137-41-7 31-Dec-10  
Methacycline hydrochloride developmental FR 3963-95-9 1-Jan-91  
Metham sodium cancer AB 137-42-8 6-Nov-98  
Metham sodium developmental AB 137-42-8 15-May-98  
Methanol developmental AB 67-56-1 16-Mar-12 47,000
(inhalation)
23,000
(oral)
Methazole developmental AB 20354-26-1 1-Dec-99  
Methimazole developmental FR 60-56-0 1-Jul-90  
Methotrexate developmental SQE 59-05-2 1-Jan-89  
Methotrexate sodium developmental FR 15475-56-6 1-Apr-90  
5-Methoxypsoralen with ultraviolet A therapy cancer SQE 484-20-8 1-Oct-88  
8-Methoxypsoralen with ultraviolet A therapy cancer LC 298-81-7 27-Feb-87  
2-Methylaziridine (Propyleneimine) cancer SQE 75-55-8 1-Jan-88 0.028
Methylazoxymethanol cancer SQE 590-96-5 1-Apr-88  
Methylazoxymethanol acetate cancer SQE 592-62-1 1-Apr-88  
Methyl bromide, as a structural fumigant developmental FR 74-83-9 1-Jan-93 810
(inhalation)
Methyl n-butyl ketone male LC 591-78-6 7-Aug-09  
Methyl carbamate cancer AB 598-55-0 15-May-98 160
Methyl chloride developmental AB 74-87-3 10-Mar-00  
Methyl chloride [Basis for listing changed effective March 7, 2014] male AB 74-87-3 7-Aug-09  
3-Methylcholanthrene cancer AB 56-49-5 1-Jan-90 0.03
5-Methylchrysene cancer SQE 3697-24-3 1-Apr-88 0.0084
(oral)
4,4'-Methylene bis(2-chloroaniline) cancer FR 101-14-4 1-Jul-87 0.5
4,4'-Methylene bis(N,N- dimethyl)benzenamine cancer LC 101-61-1 1-Oct-89 20
4,4'-Methylene bis(2-methylaniline) cancer SQE 838-88-0 1-Apr-88 0.8
4,4'-Methylenedianiline cancer SQE 101-77-9 1-Jan-88 0.4
4,4'-Methylenedianiline dihydrochloride cancer SQE 13552-44-8 1-Jan-88 0.6
Methyleugenol cancer AB 93-15-2 16-Nov-01  
Methylhydrazine and its salts cancer AB --- 1-Jul-92  
Methylhydrazine         0.058 (oral)
0.090
(inhalation)
Methylhydrazine sulfate         0.18
2-Methylimidazole cancer LC 693-98-1 22-Jun-12  
4-Methylimidazole cancer AB 822-36-6 7-Jan-11 29
Methyl iodide cancer SQE 74-88-4 1-Apr-88  
Methyl isobutyl ketone cancer LC 108-10-1 4-Nov-11  
Methyl isobutyl ketone (MIBK) developmental AB 108-10-1 28-Mar-14  
Methyl isocyanate (MIC) developmental, female SQE 624-83-9 12-Nov-10  
Methyl isopropyl ketone [Delisted April 4, 2014]          
Methyl mercury developmental SQE --- 1-Jul-87  
Methylmercury compounds cancer AB --- 1-May-96  
Methyl methanesulfonate cancer SQE 66-27-3 1-Apr-88 7
2-Methyl-1-nitroanthraquinone (of uncertain purity) cancer SQE 129-15-7 1-Apr-88 0.2
N-Methyl-N'-nitro-N-nitrosoguanidine cancer SQE 70-25-7 1-Apr-88 0.08
N-Methylolacrylamide cancer AB 924-42-5 1-Jul-90  
N-Methylpyrrolidone developmental AB 872-50-4 15-Jun-01 3200 (inhalation) 17000 (dermal)
a-Methyl styrene (alpha-Methylstyrene) cancer LC 98-83-9 2-Nov-12  
a-Methyl styrene [Delisted April 4, 2014]          
Methyltestosterone developmental FR 58-18-4 1-Apr-90  
Methylthiouracil cancer LC 56-04-2 1-Oct-89 2
Metiram cancer AB 9006-42-2 1-Jan-90  
Metiram developmental AB 9006-42-2 30-Mar-99  
Metronidazole cancer SQE 443-48-1 1-Jan-88  
Michler's ketone cancer SQE 90-94-8 1-Jan-88 0.8
Midazolam hydrochloride developmental FR 59467-96-8 1-Jul-90  
Minocycline hydrochloride (internal use) developmental FR 13614-98-7 1-Jan-92  
Mirex cancer SQE 2385-85-5 1-Jan-88 0.04
Misoprostol developmental FR 59122-46-2 1-Apr-90  
Mitomycin C cancer SQE 50-07-7 1-Apr-88 0.00009
Mitoxantrone hydrochloride developmental FR 70476-82-3 1-Jul-90  
Molinate developmental, female, male AB 2212-67-1 11-Dec-09  
MON 4660 (dichloroacetyl-1-oxa-4- azaspiro(4,5)-decane cancer AB 71526-07-3 22-Mar-11  
MON 13900 (furilazole) cancer AB 121776-33-8 22-Mar-11  
3-Monochloropropane-1,2-diol (3- MCDP) cancer SQE 96-24-2 8-Oct-10  
Monocrotaline cancer SQE 315-22-0 1-Apr-88 0.07
MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture) cancer LC 113803-47-7 4-Nov-11  
5-(Morpholinomethyl)-3-[(5- nitrofurfurylidene)-mino]-2- oxazolidinone cancer SQE 139-91-3 1-Apr-88 0.18
Mustard Gas cancer LC 505-60-2 27-Feb-87  
MX (3-chloro-4-dichloromethyl-5- hydroxy-2(5H)-furanone) cancer SQE 77439-76-0 22-Dec-00 0.11
Myclobutanil developmental, male AB 88671-89-0 16-Apr-99  
Nabam developmental AB 142-59-6 30-Mar-99  
Nafarelin acetate developmental FR 86220-42-0 1-Apr-90  
Nafenopin cancer SQE 3771-19-5 1-Apr-88  
Nalidixic acid cancer AB 389-08-2 15-May-98 28
Naphthalene cancer AB 91-20-3 19-Apr-02 5.8
1-Naphthylamine cancer LC 134-32-7 1-Oct-89  
2-Naphthylamine cancer LC 91-59-8 27-Feb-87 0.4
Neomycin sulfate (internal use) developmental FR 1405-10-3 1-Oct-92  
Netilmicin sulfate developmental FR 56391-57-2 1-Jul-90  
Nickel (Metallic) cancer LC 7440-02-0 1-Oct-89  
Nickel acetate cancer LC 373-02-4 1-Oct-89  
Nickel carbonate cancer LC 3333-67-3 1-Oct-89  
Nickel carbonyl cancer SQE 13463-39-3 1-Oct-87  
Nickel carbonyl developmental AB 13463-39-3 1-Sep-96  
Nickel compounds cancer LC --- 7-May-04  
Nickel hydroxide cancer LC 12054-48-7;
12125-56-3		 1-Oct-89  
Nickelocene cancer LC 1271-28-9 1-Oct-89  
Nickel oxide cancer LC 1313-99-1 1-Oct-89  
Nickel refinery dust from the pyrometallurgical process cancer SQE --- 1-Oct-87 0.8
Nickel subsulfide cancer SQE 12035-72-2 1-Oct-87 0.4
Nicotine developmental FR 54-11-5 1-Apr-90  
Nifedipine developmental, female, male FR 21829-25-4 29-Jan-99  
Nimodipine developmental FR 66085-59-4 24-Apr-01  
Niridazole cancer SQE 61-57-4 1-Apr-88  
Nitrapyrin cancer AB 1929-82-4 5-Oct-05  
Nitrapyrin developmental AB 1929-82-4 30-Mar-99  
Nitrilotriacetic acid cancer SQE 139-13-9 1-Jan-88 100
Nitrilotriacetic acid, trisodium salt monohydrate cancer SQE 18662-53-8 1-Apr-89 70
5-Nitroacenaphthene cancer SQE 602-87-9 1-Apr-88 6
5-Nitro-o-anisidine [Delisted December 8, 2006]          
o-Nitroanisole cancer AB 91-23-6 1-Oct-92  
Nitrobenzene cancer AB 98-95-3 26-Aug-97  
Nitrobenzene male AB 98-95-3 30-Mar-10  
4-Nitrobiphenyl cancer SQE 92-93-3 1-Apr-88  
6-Nitrochrysene cancer AB 7496-02-8 1-Oct-90  
Nitrofen (technical grade) cancer SQE 1836-75-5 1-Jan-88 9
2-Nitrofluorene cancer AB 607-57-8 1-Oct-90  
Nitrofurantoin male AB 67-20-9 1-Apr-91  
Nitrofurazone cancer AB 59-87-0 1-Jan-90 0.5
1-[(5-Nitrofurfurylidene)-amino]-2- imidazolidinone cancer SQE 555-84-0 1-Apr-88 0.4
N-[4-(5-Nitro-2-furyl)-2- thiazolyl]acetamide cancer SQE 531-82-8 1-Apr-88 0.5
Nitrogen mustard (Mechlorethamine) cancer SQE 51-75-2 1-Jan-88  
Nitrogen mustard (Mechlorethamine) developmental SQE 51-75-2 1-Jan-89  
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride) cancer SQE 55-86-7 1-Apr-88  
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride) developmental FR 55-86-7 1-Jul-90  
Nitrogen mustard N-oxide cancer SQE 126-85-2 1-Apr-88  
Nitrogen mustard N-oxide hydrochloride cancer SQE 302-70-5 1-Apr-88  
Nitromethane cancer AB 75-52-5 1-May-97 39
2-Nitropropane cancer SQE 79-46-9 1-Jan-88  
1-Nitropyrene cancer AB 5522-43-0 1-Oct-90  
4-Nitropyrene cancer AB 57835-92-4 1-Oct-90  
N-Nitrosodiethanolamine cancer SQE 1116-54-7 1-Jan-88 0.3
N-Nitrosodiethylamine cancer SQE 55-18-5 1-Oct-87 0.02
N-Nitrosodimethylamine cancer SQE 62-75-9 1-Oct-87 0.04
N-Nitrosodi-n-butylamine cancer SQE 924-16-3 1-Oct-87 0.06
N-Nitrosodi-n-propylamine cancer SQE 621-64-7 1-Jan-88 0.1
p-Nitrosodiphenylamine cancer SQE 156-10-5 1-Jan-88 30
N-Nitrosodiphenylamine cancer SQE 86-30-6 1-Apr-88 80
3-(N-Nitrosomethylamino) propionitrile cancer AB 60153-49-3 1-Apr-90  
4-(N-Nitrosomethylamino)-1-(3- pyridyl)1-butanone cancer AB 64091-91-4 1-Apr-90 0.014
N-Nitrosomethylethylamine cancer LC 10595-95-6 1-Oct-89 0.03
N-Nitrosomethylvinylamine cancer SQE 4549-40-0 1-Jan-88  
N-Nitrosomorpholine cancer SQE 59-89-2 1-Jan-88 0.1
N-Nitroso-N-ethylurea cancer SQE 759-73-9 1-Oct-87 0.03
N-Nitroso-N-methylurea cancer SQE 684-93-5 1-Oct-87 0.006
N-Nitroso-N-methylurethane cancer SQE 615-53-2 1-Apr-88 0.006
N-Nitrosonornicotine cancer SQE 16543-55-8 1-Jan-88 0.5
N-Nitrosopiperidine cancer SQE 100-75-4 1-Jan-88 0.07
N-Nitrosopyrrolidine cancer SQE 930-55-2 1-Oct-87 0.3
N-Nitrososarcosine cancer SQE 13256-22-9 1-Jan-88  
o-Nitrotoluene cancer AB 88-72-2 15-May-98  
Nitrous oxide [Basis for listing changed effective November 8, 2013] developmental, female AB 10024-97-2 1-Aug-08  
Norethisterone (Norethindrone) cancer LC 68-22-4 1-Oct-89  
Norethisterone (Norethindrone) developmental FR 68-22-4 1-Apr-90  
Norethisterone acetate (Norethindrone acetate) developmental FR 51-98-9 1-Oct-91  
Norethisterone (Norethindrone) /Ethinyl estradiol developmental FR 568-22-4/
7-63-6		 1-Apr-90  
Norethisterone (Norethindrone) /Mestranol developmental FR 68-22-4/
72-33-3		 1-Apr-90  
Norethynodrel cancer AB 68-23-5 27-Feb-01  
Norgestrel developmental FR 6533-00-2 1-Apr-90  
Ochratoxin A cancer AB 303-47-9 1-Jul-90  
Oil Orange SS cancer SQE 2646-17-5 1-Apr-88  
Oral contraceptives, combined cancer LC --- 1-Oct-89  
Oral contraceptives, sequential cancer LC --- 1-Oct-89  
Oryzalin cancer AB 19044-88-3 12-Sep-08  
Oxadiazon cancer SQE 19666-30-9 1-Jul-91  
Oxadiazon developmental AB 19666-30-9 15-May-98  
Oxazepam cancer AB 604-75-1 1-Oct-94  
Oxazepam developmental FR 604-75-1 1-Oct-92  
p,p'-Oxybis(benzenesulfonyl hydrazide) [Delisted December 13, 2013]          
Oxydemeton methyl female, male AB 301-12-2 6-Nov-98  
Oxymetholone cancer SQE 434-07-1 1-Jan-88  
Oxymetholone developmental FR 434-07-1 1-May-97  
Oxytetracycline (internal use) developmental FR 79-57-2 1-Jan-91  
Oxytetracycline hydrochloride (internal use) developmental FR 2058-46-0 1-Oct-91  
Oxythioquinox (Chinomethionat) cancer AB 2439-01-2 20-Aug-99  
Oxythioquinox (Chinomethionat) developmental AB 2439-01-2 6-Nov-98  
Paclitaxel developmental, female, male FR 33069-62-4 26-Aug-97  
Palygorskite fibers (> 5mm in length) cancer AB 12174-11-7 28-Dec-99  
Panfuran S cancer SQE 794-93-4 1-Jan-88  
Paramethadione developmental FR 115-67-3 1-Jul-90  
Penicillamine developmental FR 52-67-5 1-Jan-91  
Pentachlorophenol cancer AB 87-86-5 1-Jan-90 40
Pentobarbital sodium developmental FR 57-33-0 1-Jul-90  
Pentosan polysulfate sodium cancer LC --- 18-Apr-14  
Pentostatin developmental FR 53910-25-1 1-Sep-96  
Phenacemide developmental FR 63-98-9 1-Jul-90  
Phenacetin cancer LC 62-44-2 1-Oct-89 300
Phenazopyridine cancer SQE 94-78-0 1-Jan-88 4
Phenazopyridine hydrochloride cancer SQE 136-40-3 1-Jan-88 5
Phenesterin cancer SQE 3546-10-9 1-Jul-89 0.005
Phenobarbital cancer AB 50-06-6 1-Jan-90 2
Phenolphthalein cancer AB 77-09-8 15-May-98  
Phenoxybenzamine cancer SQE 59-96-1 1-Apr-88 0.2
Phenoxybenzamine hydrochloride cancer SQE 63-92-3 1-Apr-88 0.3
Phenprocoumon developmental FR 435-97-2 1-Oct-92  
o-Phenylenediamine and its salts cancer AB 95-54-5 15-May-98  
o-Phenylenediamine         26
o-Phenylenediamine dihydochloride         44
Phenyl glycidyl ether cancer AB 122-60-1 1-Oct-90 5
Phenyl glycidyl ether [Delisted April 4, 2014]   LC      
Phenylhydrazine and its salts cancer AB --- 1-Jul-92  
Phenylhydrazine         1
Phenylhydrazine hydrochloride         1.4
o-Phenylphenate, sodium cancer AB 132-27-4 1-Jan-90 200
o-Phenylphenol cancer AB 90-43-7 4-Aug-00  
Phenylphosphine [Basis for listing changed effective June 6, 2014] developmental male LC SQE 638-21-1 7-Aug-09  
PhiP(2-Amino-1-methyl-6- phenylimidazol[4,5-b]pyridine) cancer AB 105650-23-5 1-Oct-94  
Pimozide developmental, female FR 2062-78-4 20-Aug-99  
Pioglitazone cancer LC 111025-46-8 18-Apr-14  
Pipobroman developmental FR 54-91-1 1-Jul-90  
Pirimicarb cancer AB 23103-98-2 1-Jul-08  
Plicamycin developmental FR 18378-89-7 1-Apr-90  
Polybrominated biphenyls cancer SQE --- 1-Jan-88 0.02
Polybrominated biphenyls developmental AB --- 1-Oct-94  
Polychlorinated biphenyls cancer LC --- 1-Oct-89 0.09
Polychlorinated biphenyls developmental SQE --- 1-Jan-91  
Polychlorinated biphenyls (containing 60 or more percent percent chlorine by molecular weight) cancer SQE --- 1-Jan-88  
Polychlorinated dibenzo-p-dioxins cancer FR --- 1-Oct-92  
Polychlorinated dibenzofurans cancer FR --- 1-Oct-92  
Polygeenan cancer SQE 53973-98-1 1-Jan-88 1200
Ponceau MX cancer SQE 3761-53-3 1-Apr-88 200
Ponceau 3R cancer SQE 3564-09-8 1-Apr-88 40
Potassium bromate cancer AB 7758-01-2 1-Jan-90 1
Potassium dimethyldithiocarbamate developmental AB 128-03-0 30-Mar-99 720
Pravastatin sodium developmental FR 81131-70-6 3-Mar-00  
Prednisolone sodium phosphate developmental FR 125-02-0 20-Aug-99  
Primidone cancer AB 125-33-7 20-Aug-99  
Procarbazine cancer SQE 671-16-9 1-Jan-88 0.05
Procarbazine hydrochloride cancer SQE 366-70-1 1-Jan-88 0.06
Procarbazine hydrochloride developmental FR 366-70-1 1-Jul-90  
Procymidone cancer AB 32809-16-8 1-Oct-94  
Progesterone cancer SQE 57-83-0 1-Jan-88  
Pronamide cancer AB 23950-58-5 1-May-96  
Propachlor cancer AB 1918-16-7 27-Feb-01  
1,3-Propane sultone cancer SQE 1120-71-4 1-Jan-88 0.3
Propargite cancer AB 2312-35-8 1-Oct-94  
Propargite developmental AB 2312-35-8 15-Jun-99  
beta-Propiolactone cancer SQE 57-57-8 1-Jan-88 0.05
Propoxur cancer AB 114-26-1 11-Aug-06  
Propylene glycol mono-t-butyl ether cancer AB 57018-52-7 11-Jun-04  
Propylene oxide cancer SQE 75-56-9 1-Oct-88  
Propylthiouracil cancer SQE 51-52-5 1-Jan-88 0.7
Propylthiouracil developmental FR 51-52-5 1-Jul-90  
Pulegone cancer LC 89-82-7 18-Apr-14  
Pymetrozine cancer AB 123312-89-0 22-Mar-11  
Pyridine cancer AB 110-86-1 17-May-02  
Pyrimethamine developmental FR 58-14-0 29-Jan-99  
Quazepam developmental FR 36735-22-5 26-Aug-97  
Quinoline and its strong acid salts cancer SQE --- 24-Oct-97  
Quizalofop-ethyl male SQE 76578-14-8 24-Dec-99 590
Radionuclides cancer SQE --- 1-Jul-89  
Reserpine cancer LC 50-55-5 1-Oct-89 0.06
Residual (heavy) fuel oils cancer AB --- 1-Oct-90  
Resmethrin cancer AB 10453-86-8 1-Jul-08  
Resmethrin developmental AB 10453-86-8 6-Nov-98  
Retinol/retinyl esters, when in daily dosages in excess of 10,000 IU, or 3,000 retinol equivalents. (NOTE: Retinol/retinyl esters are required and essential for maintenance of normal reproductive function. The recommended daily level during pregnancy is 8,000 IU.) developmental SQE --- 1-Jul-89  
Ribavirin developmental FR 36791-04-5 1-Apr-90  
Ribavirin male FR 36791-04-5 27-Feb-01  
Riddelliine cancer LC 23246-96-0 3-Dec-04  
Rifampin developmental, female FR 13292-46-1 27-Feb-01  
Saccharin [Delisted April 6, 2001]          
Saccharin, sodium [Delisted January 17, 2003]          
Safrole cancer SQE 94-59-7 1-Jan-88 3
Salted fish, Chinese-style cancer LC --- 29-Apr-11  
Secobarbital sodium developmental FR 309-43-3 1-Oct-92  
Selenium sulfide cancer LC 7446-34-6 1-Oct-89  
Sermorelin acetate developmental FR --- 20-Aug-99  
Shale-oils cancer AB 68308-34-9 1-Apr-90  
Silica, crystalline (airborne particles of respirable size) cancer SQE --- 1-Oct-88  
Sodium dimethyldithiocarbamate developmental AB 128-04-1 30-Mar-99 23 (oral)
58 (oral) as
a 40%
pesticidal formulation
Sodium fluoroacetate male AB 62-74-8 6-Nov-98  
Soots, tars, and mineral oils (untreated and mildly treated oils and used engine oils) cancer LC --- 27-Feb-87  
Spirodiclofen cancer AB 148477-71-8 8-Oct-10  
Spironolactone cancer FR 52-01-7 1-May-97  
Stanozolol cancer FR 10418-03-8 1-May-97  
Sterigmatocystin cancer SQE 10048-13-2 1-Apr-88 0.02
Streptomycin sulfate developmental   3810-74-0 1-Jan-91  
Streptozocin (streptozotocin) developmental, female, male FR 18883-66-4 20-Aug-99  
Streptozotocin (streptozocin) cancer SQE 18883-66-4 1-Jan-88 0.006
Strong inorganic acid mists containing sulfuric acid cancer AB --- 14-Mar-03  
Styrene oxide cancer SQE 96-09-3 1-Oct-88 4
Sulfallate cancer SQE 95-06-7 1-Jan-88 4
Sulfasalazine (salicylazosulfapyridine) cancer AB 599-79-1 15-May-98  
Sulfasalazine (salicylazosulfapyridine) male FR 599-79-1 29-Jan-99  
Sulfur dioxidee developmental SQE 7446-09-5 29-Jul-11 10000
Sulindac developmental, female FR 38194-50-2 29-Jan-99  
Talc containing asbestiform fibers cancer AB --- 1-Apr-90  
Tamoxifen and its salts cancer SQE 10540-29-1 1-Sep-96  
Tamoxifen citrate developmental FR 54965-24-1 1-Jul-90  
Temazepam developmental FR 846-50-4 1-Apr-90  
Teniposide developmental FR 29767-20-2 1-Sep-96  
Terbacil developmental AB 5902-51-2 18-May-99  
Terrazole cancer AB 2593-15-9 1-Oct-94  
Testosterone and its esters cancer SQE 58-22-0 1-Apr-88  
Testosterone cypionate developmental FR 58-20-8 1-Oct-91  
Testosterone enanthate developmental FR 315-37-7 1-Apr-90  
3,3',4,4'-Tetrachloroazobenzene cancer AB 14047-09-7 24-Jul-12  
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) cancer SQE 1746-01-6 1-Jan-88 0.000005
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) developmental AB 1746-01-6 1-Apr-91  
1,1,1,2-Tetrachloroethane cancer LC 630-20-6 13-Sep-13  
1,1,2,2-Tetrachloroethane cancer AB 79-34-5 1-Jul-90 3
Tetrachloroethylene (Perchloroethylene) cancer SQE 127-18-4 1-Apr-88 14
p-a,a,a-Tetrachlorotoluene cancer AB 5216-25-1 1-Jan-90  
Tetracycline (internal use) developmental FR 60-54-8 1-Oct-91  
Tetracyclines (internal use) developmental FR --- 1-Oct-92  
Tetracycline hydrochloride (internal use) developmental FR 64-75-5 1-Jan-91  
Tetrafluoroethylene cancer AB 116-14-3 1-May-97  
Tetranitromethane cancer AB 509-14-8 1-Jul-90 0.059
Thalidomide developmental SQE 50-35-1 1-Jul-87  
Thioacetamide cancer SQE 62-55-5 1-Jan-88 0.1
4,4'-Thiodianiline cancer SQE 139-65-1 1-Apr-88 0.05
Thiodicarb cancer AB 59669-26-0 20-Aug-99  
Thioguanine developmental FR 154-42-7 1-Jul-90  
Thiophanate methyl female, male AB 23564-05-8 18-May-99 600 (oral)
Thiouracil cancer AB 141-90-2 11-Jun-04  
Thiourea cancer SQE 62-56-6 1-Jan-88 10
Thorium dioxide cancer LC 1314-20-1 27-Feb-87  
Titanium dioxide (airborne, unbound particles of respirable size) cancer LC --- 2-Sep-11  
Tobacco, oral use of smokeless products cancer SQE --- 1-Apr-88  
Tobacco smoke cancer SQE --- 1-Apr-88  
Tobacco smoke (primary) developmental, female, male SQE --- 1-Apr-88  
Tobramycin sulfate developmental FR 49842-07-1 1-Jul-90  
Toluene developmental SQE 108-88-3 1-Jan-91 7000c
Toluene [Basis for the removal of female reproductive endpoint effective March 7, 2014]          
Toluene diisocyanate cancer LC 26471-62-5 1-Oct-89 20
o-Toluidine cancer SQE 95-53-4 1-Jan-88 4
o-Toluidine hydrochloride cancer SQE 636-21-5 1-Jan-88 5
para-Toluidine [Delisted October 29, 1999]          
Toxaphene (Polychlorinated camphenes) cancer SQE 8001-35-2 1-Jan-88 0.6
Toxins derived from Fusarium moniliforme (Fusarium verticillioides) cancer LC --- 7-Aug-09  
Treosulfan cancer LC 299-75-2 27-Feb-87  
Triadimefon developmental, female, male AB 43121-43-3 30-Mar-99  
Triamterene cancer LC 396-01-0 18-Apr-14  
Triazolam developmental FR 28911-01-5 1-Apr-90  
S,S,S-Tributyl phosphorotrithioate (Tribufos, DEF) cancer AB 78-48-8 25-Feb-11  
Tributyltin methacrylate developmental AB 2155-70-6 1-Dec-99  
Trichlormethine (Trimustine hydrochloride) cancer AB 817-09-4 1-Jan-92  
Trichloroacetic acid cancer LC 76-03-9 13-Sep-13  
Trichloroethylene cancer SQE 79-01-6 1-Apr-88 14 (oral)
50
(inhalation)
Trichloroethylene developmental, male AB 79-01-6 31-Jan-14  
2,4,6-Trichlorophenol cancer SQE 88-06-2 1-Jan-88 10
1,2,3-Trichloropropane cancer AB 96-18-4 1-Oct-92  
Trientine hydrochloride developmental FR 38260-01-4 27-Feb-01  
Triforine developmental AB 26644-46-2 18-Jun-99  
1,3,5-Triglycidyl-s-triazinetrione [Delisted December 13, 2013]          
Trilostane developmental FR 13647-35-3 1-Apr-90  
Trimethadione developmental FR 127-48-0 1-Jan-91  
2,4,5-Trimethylaniline and its strong acid salts cancer SQE --- 24-Oct-97  
Trimethyl phosphate cancer AB 512-56-1 1-May-96 24
Trimetrexate glucuronate developmental FR 82952-64-5 26-Aug-97  
2,4.6-Trinitrotoluene (TNT) cancer SQE 118-96-7 19-Dec-08 8.2
Triphenyltin hydroxide cancer AB 76-87-9 1-Jul-92  
Triphenyltin hydroxide developmental AB 76-87-9 18-Mar-02  
Tris(aziridinyl)-p-benzoquinone (Triaziquone) [Delisted December 8, 2006]          
Tris(1-aziridinyl)phosphine sulfide (Thiotepa) cancer SQE 52-24-4 1-Jan-88 0.06
Tris(2-chloroethyl) phosphate cancer AB 115-96-8 1-Apr-92  
Tris(2,3-dibromopropyl)phosphate cancer SQE 126-72-7 1-Jan-88 0.3
Tris(1,3-dichloro-2-propyl) phosphate (TDCPP) cancer SQE 13674-87-8 28-Oct-11 5.4
Trp-P-1 (Tryptophan-P-1) cancer SQE 62450-06-0 1-Apr-88 0.03
Trp-P-2 (Tryptophan-P-2) cancer SQE 62450-07-1 1-Apr-88 0.2
Trypan blue (commercial grade) cancer LC 72-57-1 1-Oct-89  
Unleaded gasoline (wholly vaporized) cancer SQE --- 1-Apr-88  
Uracil mustard cancer SQE 66-75-1 1-Apr-88  
Uracil mustard developmental, female, male FR 66-75-1 1-Jan-92  
Urethane (Ethyl carbamate) cancer SQE 51-79-6 1-Jan-88 0.7
Urethane (Ethyl carbamate) developmental AB 51-79-6 1-Oct-94  
Urofollitropin developmental FR 97048-13-0 1-Apr-90  
Valproate (Valproic acid) developmental SQE 99-66-1 1-Jul-87  
Vanadium pentoxide (orthorhombic crystalline form) cancer AB 1314-62-1 11-Feb-05  
Vinblastine sulfate developmental FR 143-67-9 1-Jul-90  
Vinclozolin cancer AB 50471-44-8 20-Aug-99  
Vinclozolin developmental AB 50471-44-8 15-May-98  
Vincristine sulfate developmental FR 2068-78-2 1-Jul-90  
Vinyl bromide cancer SQE 593-60-2 1-Oct-88  
Vinyl chloride cancer LC 75-01-4 27-Feb-87 3
4-Vinylcyclohexene cancer AB 100-40-3 1-May-96  
4-Vinylcyclohexene [Basis for the removal of male reproductive endpoint effective December 20, 2013] female SQE 100-40--3 7-Aug-09  
4-Vinyl-1-cyclohexene diepoxide (Vinyl cyclohexenedioxide) cancer AB 106-87-6 1-Jul-90  
Vinyl cyclohexene dioxide (4-Vinyl-1- cyclohexene diepoxide) [Basis for the removal of male reproductive endpoint effective December 20, 2013] female SQE 106-87-6 1-Aug-08  
Vinyl fluoride cancer AB 75-02-5 1-May-97  
Vinyl trichloride (1,1,2- Trichloroethane) cancer AB 79-00-5 1-Oct-90 10
Warfarin developmental SQE 81-81-2 1-Jul-87  
Wood dust cancer LC --- 18-Dec-09  
           
2,6-Xylidine (2,6-Dimethylaniline) cancer AB 87-62-7 1-Jan-91 110
           
Zalcitabine cancer LC 7481-89-2 7-Aug-09  
Zidovudine (AZT) cancer LC 30516-87-1 18-Dec-09  
Zileuton cancer, developmental, female FR 111406-87-2 22-Dec-00  
Zineb [Delisted October 29, 1999]          

Back to Chapter Seven

Proceed to Chapter Nine

Details

Article ID: 132020
Created
Thu 4/8/21 9:22 PM
Modified
Mon 7/4/22 12:26 PM
Effective Date
If the date on which this document became/becomes enforceable differs from the Origination or Last Revision, this attribute reflects the date on which it is/was enforcable.
04/22/2022 12:00 AM
Issuing Officer
Name of the document Issuing Officer. This is the individual whose organizational authority covers the policy scope and who is primarily responsible for the policy.
Issuing Officer Title
Title of the person who is primarily responsible for issuing this policy.
Executive Director
Last Review
Date on which the most recent document review was completed.
04/22/2022 12:00 AM
Last Revised
Date on which the most recent changes to this document were approved.
04/22/2022 12:00 AM
Next Review
Date on which the next document review is due.
09/01/2027 12:00 AM
Origination
Date on which the original version of this document was first made official.
07/01/2014 12:00 AM
Responsible Unit
School, Department, or other organizational unit issuing this document.
Environment, Health and Safety